Venetoclax tablets (10, 50, and 100 mg) and newly developed oral powder formulations were evaluated to establish interchangeability of the different formulations with the 100 mg tablets and to enable administration with different dosing vehicles.

Bioavailability data and exposure–response analyses demonstrated that the smaller-sized venetoclax tablets and the oral powder formulations could be used interchangeably to administer appropriate doses of venetoclax based on patients’ preference.

Apple juice, apple sauce, and yogurt can be used to facilitate venetoclax powder formulation administration.